SAR131672

SAR131672 is a selective small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). It has been investigated in preclinical models for its ability to modulate lymphangiogenesis—the formation of new lymphatic vessels—and inflammation. By inhibiting VEGFR3 signaling, SAR131672 reduces the proliferation of lymphatic vessels and the recruitment of inflammatory cells. Research has specifically explored its therapeutic potential in murine models of systemic lupus erythematosus (SLE) and lupus nephritis, where it demonstrated the ability to ameliorate renal inflammation and decrease the expression of pro-inflammatory cytokines and chemokines such as ICAM-1, VCAM-1, and MCP-1. While the code name SAR131672 appears in specific academic literature, it is closely related to or potentially a variant of SAR131675, a well-characterized VEGFR3 inhibitor developed by Sanofi.